Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc.RARE · Entity 4337 | Director | June 24, 2021 | June 28, 2021 |
| X4 Pharmaceuticals, IncXFOR · Entity 5638 | Director | June 10, 2024 | June 11, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ultragenyx Pharmaceutical Inc.
Report date June 24, 2021 · Filed June 28, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 66,849 |
Reported balance
After 2021-06-24 transaction · row 1
1 source rowRow 1 · 2021-06-24 · Grant · Acquired 2,145 · Balance 66,849 F1: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 24, 2022. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $93.20 · Expires 2031-06-24 | Direct | 4,125 |
Reported balance
After 2021-06-24 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-06-24 · Grant · Acquired 4,125 · Balance 4,125 F4: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 24, 2022. |
| Common StockSEC Table I · non-derivative | IndirectBy trust | 70,350 |
Reported balance
Holding disclosure · report date 2021-06-24 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 70,350 F2: These shares are held in a trust for the benefit of the Reporting Person's spouse and children. The Reporting Person's spouse and nephew are trustees of the trust. |
| Common StockSEC Table I · non-derivative | IndirectBy trust | 10,456 |
Reported balance
Holding disclosure · report date 2021-06-24 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 10,456 F3: These shares are held in a grantor retained annuity trust. The Reporting Person is the trustee of the trusts. |
Filing footnotes · ownership attribution and instrument terms
F1: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 24, 2022.
F2: These shares are held in a trust for the benefit of the Reporting Person's spouse and children. The Reporting Person's spouse and nephew are trustees of the trust.
F3: These shares are held in a grantor retained annuity trust. The Reporting Person is the trustee of the trusts.
F4: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 24, 2022.
X4 Pharmaceuticals, Inc
Report date June 10, 2024 · Filed June 11, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 96,667 |
Reported balance
After 2024-06-10 transaction · row 1
1 source rowRow 1 · 2024-06-10 · Grant · Acquired 45,000 · Balance 96,667 F1: Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
APPLIED GENETIC TECHNOLOGIES CORP
Report date November 30, 2022 · Filed December 01, 2022
Section 16 reporting ended · disclosed 2022-12-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-11-30 transaction · row 1
1 source rowRow 1 · 2022-11-30 · Other · Disposed 8,500 · Balance 0 F1: Includes 1,500 shares held by the Reporting Person's wife in a self-directed IRA. F2: At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (1) $0.34 per share of common stock of the Issuer ("Common Stock"), without interest and less any applicable withholding taxes (the "Cash Consideration"); and (2) one contingent value right ("CVR") per share of Common Stock representing the right to receive potential milestone payments, currently estimated to be up to approximately $0.73 per CVR in the aggregate (without interest and less any applicable withholding taxes) (the Cash Consideration plus one CVR, collectively, as such amount may be increased in accordance with the terms of the Merger Agreement, the "Offer Price"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.40 · Expires 2028-09-20 | Direct | 0 |
Reported balance
After 2022-11-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-11-30 · Disposition to issuer · Disposed 25,000 · Balance 0 F3: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.90 · Expires 2028-11-15 | Direct | 0 |
Reported balance
After 2022-11-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-11-30 · Disposition to issuer · Disposed 10,000 · Balance 0 F3: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.02 · Expires 2029-12-04 | Direct | 0 |
Reported balance
After 2022-11-30 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-11-30 · Disposition to issuer · Disposed 10,000 · Balance 0 F3: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.72 · Expires 2030-12-16 | Direct | 0 |
Reported balance
After 2022-11-30 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-11-30 · Disposition to issuer · Disposed 12,000 · Balance 0 F3: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.17 · Expires 2031-11-30 | Direct | 0 |
Reported balance
After 2022-11-30 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-11-30 · Disposition to issuer · Disposed 14,000 · Balance 0 F3: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 1,500 shares held by the Reporting Person's wife in a self-directed IRA.
F2: At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (1) $0.34 per share of common stock of the Issuer ("Common Stock"), without interest and less any applicable withholding taxes (the "Cash Consideration"); and (2) one contingent value right ("CVR") per share of Common Stock representing the right to receive potential milestone payments, currently estimated to be up to approximately $0.73 per CVR in the aggregate (without interest and less any applicable withholding taxes) (the Cash Consideration plus one CVR, collectively, as such amount may be increased in accordance with the terms of the Merger Agreement, the "Offer Price"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price.
F3: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2024 Filed Jun 11, 2024 20:13 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-027677 · wk-form4_1718136796.xml · nonDerivative · entry 1 Aliski William · CIK 0001598426 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,667 F1 · shares: Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer. Read SEC document |
| June 13, 2023 Filed Jun 14, 2023 21:10 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-022099 · wk-form4_1686777025.xml · nonDerivative · entry 1 Aliski William · CIK 0001598426 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,667 F1 · shares: Represents restricted stock units (?RSUs?) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer?s next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer. Read SEC document |
| November 30, 2022 Filed Dec 1, 2022 09:21 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Disposition to issuerStock Option (Right to Buy) · Derivative | 14,000 | Not disclosed Strike: $2.17 | Not disclosed |
DisclosureSEC source: 0001062993-22-023027 · form4.xml · derivative · entry 6 Aliski William · CIK 0001598426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,000 shares Expires 2031-11-30 F3 · price: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. F3 · derivative.exercise_date: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. Read SEC document |
| November 30, 2022 Filed Dec 1, 2022 09:21 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Disposition to issuerStock Option (Right to Buy) · Derivative | 12,000 | Not disclosed Strike: $4.72 | Not disclosed |
DisclosureSEC source: 0001062993-22-023027 · form4.xml · derivative · entry 5 Aliski William · CIK 0001598426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2030-12-16 F3 · price: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. F3 · derivative.exercise_date: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. Read SEC document |
| November 30, 2022 Filed Dec 1, 2022 09:21 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $3.02 | Not disclosed |
DisclosureSEC source: 0001062993-22-023027 · form4.xml · derivative · entry 4 Aliski William · CIK 0001598426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2029-12-04 F3 · price: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. F3 · derivative.exercise_date: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. Read SEC document |
| November 30, 2022 Filed Dec 1, 2022 09:21 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $6.90 | Not disclosed |
DisclosureSEC source: 0001062993-22-023027 · form4.xml · derivative · entry 3 Aliski William · CIK 0001598426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2028-11-15 F3 · price: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. F3 · derivative.exercise_date: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. Read SEC document |
| November 30, 2022 Filed Dec 1, 2022 09:21 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Disposition to issuerStock Option (Right to Buy) · Derivative | 25,000 | Not disclosed Strike: $4.40 | Not disclosed |
DisclosureSEC source: 0001062993-22-023027 · form4.xml · derivative · entry 2 Aliski William · CIK 0001598426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2028-09-20 F3 · price: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. F3 · derivative.exercise_date: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. Read SEC document |
| November 30, 2022 Filed Dec 1, 2022 09:21 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | OtherCommon Stock | 8,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-22-023027 · form4.xml · nonDerivative · entry 1 Aliski William · CIK 0001598426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Includes 1,500 shares held by the Reporting Person's wife in a self-directed IRA. F2 · shares: At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (1) $0.34 per share of common stock of the Issuer ("Common Stock"), without interest and less any applicable withholding taxes (the "Cash Consideration"); and (2) one contingent value right ("CVR") per share of Common Stock representing the right to receive potential milestone payments, currently estimated to be up to approximately $0.73 per CVR in the aggregate (without interest and less any applicable withholding taxes) (the Cash Consideration plus one CVR, collectively, as such amount may be increased in accordance with the terms of the Merger Agreement, the "Offer Price"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price. F2 · price: At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (1) $0.34 per share of common stock of the Issuer ("Common Stock"), without interest and less any applicable withholding taxes (the "Cash Consideration"); and (2) one contingent value right ("CVR") per share of Common Stock representing the right to receive potential milestone payments, currently estimated to be up to approximately $0.73 per CVR in the aggregate (without interest and less any applicable withholding taxes) (the Cash Consideration plus one CVR, collectively, as such amount may be increased in accordance with the terms of the Merger Agreement, the "Offer Price"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price. Read SEC document |
| June 06, 2022 Filed Jun 27, 2022 20:15 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 6,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-018048 · wf-form4_165636091026183.xml · nonDerivative · entry 1 Aliski William · CIK 0001598426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,667 F1 · shares: Represents an annual grant of restricted stock units ("RSUs") for service as a director to the Issuer. The RSUs will vest in two equal annual installments on June 6, 2023 and June 6, 2024, subject to the Reporting Person continuing to provide service to the Issuer through the applicable vesting dates. F2 · balance_after: Represents unvested RSUs. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 18:43 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | GrantStock Option (right to buy) · Derivative | 14,000 | $0.00 Strike: $2.17 | $0.00 |
DisclosureSEC source: 0001062993-21-012049 · form4.xml · derivative · entry 1 Aliski William · CIK 0001598426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2031-11-30 F1 · derivative.exercise_date: The option becomes exercisable in equal monthly installments over one year from the date of grant. Read SEC document |
| June 24, 2021 Filed Jun 28, 2021 22:26 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 4,125 | $0.00 Strike: $93.20 | $0.00 |
DisclosureSEC source: 0001209191-21-043547 · doc4.xml · derivative · entry 4 Aliski William · CIK 0001598426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,125 Underlying: Common Stock · 4,125 shares Expires 2031-06-24 F4 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 24, 2022. Read SEC document |
| June 24, 2021 Filed Jun 28, 2021 22:26 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 2,145 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-043547 · doc4.xml · nonDerivative · entry 1 Aliski William · CIK 0001598426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,849 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 24, 2022. Read SEC document |
| June 02, 2021 Filed Jun 2, 2021 21:03 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantStock Option (right to buy) · Derivative | 6,000 | $9.50 Strike: $9.50 | $57,000.00 |
DisclosureSEC source: 0001628280-21-011546 · wf-form4_162266781755759.xml · derivative · entry 1 Aliski William · CIK 0001598426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2031-06-02 F1 · derivative.exercise_date: 8.3333% of the shares subject to the option shall vest on July 2, 2021, with the remainder vesting in equal monthly installments of 8.333% of the shares subject to the option until the 12-month anniversary of the date of the grant (or, if earlier, the date of the Issuer's next annual meeting of stockholders following the date of the grant) subject to the Reporting Person continuing to provide services through each such date. Read SEC document |
| February 23, 2021 Filed Feb 23, 2021 19:30 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-013100 · doc4.xml · nonDerivative · entry 3 Aliski William · CIK 0001598426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,704 F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 19:30 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $97.85 | $0.00 |
DisclosureSEC source: 0001209191-21-013100 · doc4.xml · derivative · entry 6 Aliski William · CIK 0001598426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2025-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vested in full on on June 9, 2016. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 19:30 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 7,500 | $149.01 | $1,117,575.00 |
DisclosureSEC source: 0001209191-21-013100 · doc4.xml · nonDerivative · entry 2 Aliski William · CIK 0001598426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,704 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.00 to $149.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 19:30 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Exercise / conversionCommon Stock | 7,500 | $97.85 | $733,875.00 |
DisclosureSEC source: 0001209191-21-013100 · doc4.xml · nonDerivative · entry 1 Aliski William · CIK 0001598426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,204 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 17:15 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $4.72 | $0.00 |
DisclosureSEC source: 0001273636-20-000009 · edgar.xml · derivative · entry 1 Aliski William · CIK 0001598426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2030-12-16 F1 · derivative.exercise_date: The option becomes exercisable in equal monthly installments over one year from the date of grant. Read SEC document |
| August 27, 2020 Filed Feb 4, 2021 01:02 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-007553 · doc5.xml · nonDerivative · entry 2 Aliski William · CIK 0001598426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,704 F1 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. F2 · balance_after: Reflects transfers of shares of common stock received from the Reporting Person's trust to the Reporting Person. Read SEC document |
| August 21, 2020 Filed Aug 25, 2020 19:56 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $58.74 | $0.00 |
DisclosureSEC source: 0001209191-20-048205 · doc4.xml · derivative · entry 6 Aliski William · CIK 0001598426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2029-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested in full on June 11, 2020, the first anniversary of the grant date. Read SEC document |
| August 21, 2020 Filed Aug 25, 2020 19:56 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 5,000 | $86.57 | $432,850.00 |
DisclosureSEC source: 0001209191-20-048205 · doc4.xml · nonDerivative · entry 2 Aliski William · CIK 0001598426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,018 Read SEC document |
| August 21, 2020 Filed Aug 25, 2020 19:56 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Exercise / conversionCommon Stock | 5,000 | $58.74 | $293,700.00 |
DisclosureSEC source: 0001209191-20-048205 · doc4.xml · nonDerivative · entry 1 Aliski William · CIK 0001598426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 26, 2020 Filed Jun 30, 2020 17:10 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 4,250 | $0.00 Strike: $76.58 | $0.00 |
DisclosureSEC source: 0001209191-20-039403 · doc4.xml · derivative · entry 5 Aliski William · CIK 0001598426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,250 Underlying: Common Stock · 4,250 shares Expires 2030-06-26 F5 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 26, 2021. Read SEC document |
| June 26, 2020 Filed Jun 30, 2020 17:10 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 2,550 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-039403 · doc4.xml · nonDerivative · entry 1 Aliski William · CIK 0001598426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,018 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 26, 2021. F2 · balance_after: Reflects transfers of shares of common stock received from the Reporting Person's trust to the Reporting Person that have taken place since the most recent prior report on Form 4. Read SEC document |
| June 10, 2020 Filed Jun 11, 2020 12:34 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantStock Option (right to buy) · Derivative | 3,427 | $0.00 Strike: $8.69 | $0.00 |
DisclosureSEC source: 0001628280-20-009240 · wf-form4_159187884350300.xml · derivative · entry 1 Aliski William · CIK 0001598426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,427 Underlying: Common Stock · 3,427 shares Expires 2030-06-09 F1 · derivative.exercise_date: 8.3333% of the shares subject to the option shall vest on July 10, 2020, with the remainder vesting in equal monthly installments of 8.333% of the shares subject to the option until the 12-month anniversary of the date of the grant (or, if earlier, the date of the Issuer's next annual meeting of stockholders following the date of the grant) subject to the Reporting Person continuing to provide services through each such date. Read SEC document |
| May 21, 2020 Filed Feb 4, 2021 01:02 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-007553 · doc5.xml · nonDerivative · entry 1 Aliski William · CIK 0001598426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,704 Read SEC document |
| May 18, 2020 Filed May 20, 2020 23:50 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $40.37 | $0.00 |
DisclosureSEC source: 0001209191-20-031055 · doc4.xml · derivative · entry 6 Aliski William · CIK 0001598426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2024-07-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option was fully vested as of June 18, 2015. Read SEC document |
| May 18, 2020 Filed May 20, 2020 23:50 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 7,500 | $74.65 | $559,875.00 |
DisclosureSEC source: 0001209191-20-031055 · doc4.xml · nonDerivative · entry 2 Aliski William · CIK 0001598426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,924 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.62 to $74.70 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| May 18, 2020 Filed May 20, 2020 23:50 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Exercise / conversionCommon Stock | 7,500 | $40.37 | $302,775.00 |
DisclosureSEC source: 0001209191-20-031055 · doc4.xml · nonDerivative · entry 1 Aliski William · CIK 0001598426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,424 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 18, 2020 Filed Jun 3, 2020 20:26 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 20,000 | $74.02 | $1,480,322.00 |
DisclosureSEC source: 0001209191-20-034010 · doc4.xml · nonDerivative · entry 1 Aliski William · CIK 0001598426 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By trust Disclosed balance after: 70,350 F1 · ownership.nature: These shares are held in a trust for the benefit of the Reporting Person's spouse and children. The Reporting Person's spouse and nephew are trustees of the trust. Read SEC document |
| December 04, 2019 Filed Dec 6, 2019 17:45 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $3.02 | $0.00 |
DisclosureSEC source: 0001273636-19-000043 · edgar.xml · derivative · entry 1 Aliski William · CIK 0001598426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-12-04 F1 · derivative.exercise_date: The option becomes exercisable on December 4, 2020. Read SEC document |
| September 18, 2019 Filed Sep 20, 2019 20:52 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantStock Option (right to buy) · Derivative | 6,854 | $0.00 Strike: $14.04 | $0.00 |
DisclosureSEC source: 0001209191-19-050347 · doc4.xml · derivative · entry 1 Aliski William · CIK 0001598426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,854 Underlying: Common Stock · 6,854 shares Expires 2029-09-18 F1 · derivative.exercise_date: 8.3333% of the shares subject to the option shall vest on September 18, 2020, with the remainder vesting in equal monthly installments of 2.7777% of the shares underlying the initial grant until the 36-month anniversary of the date of the grant, subject the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| June 11, 2019 Filed Jun 13, 2019 21:00 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $58.74 | $0.00 |
DisclosureSEC source: 0001209191-19-036832 · doc4.xml · derivative · entry 5 Aliski William · CIK 0001598426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2029-06-11 F5 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 11, 2020. Read SEC document |
| June 11, 2019 Filed Jun 13, 2019 21:00 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-036832 · doc4.xml · nonDerivative · entry 1 Aliski William · CIK 0001598426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,924 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 11, 2020. F2 · balance_after: Reflects transfers of directly owned shares of common stock to the Reporting Person's trusts that have taken place since the most recent prior report on Form 4. Read SEC document |
| December 14, 2018 Filed Dec 18, 2018 20:20 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | PurchaseCommon Stock | 500 | $3.24 | $1,620.00 |
DisclosureSEC source: 0001273636-18-000085 · edgar.xml · nonDerivative · entry 3 Aliski William · CIK 0001598426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 F1 · balance_after: Includes 1,500 shares held by the Reporting Person's wife in a self-directed IRA. Read SEC document |
| December 14, 2018 Filed Dec 18, 2018 20:20 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | PurchaseCommon Stock | 4,300 | $3.25 | $13,975.00 |
DisclosureSEC source: 0001273636-18-000085 · edgar.xml · nonDerivative · entry 2 Aliski William · CIK 0001598426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 F1 · balance_after: Includes 1,500 shares held by the Reporting Person's wife in a self-directed IRA. Read SEC document |
| December 14, 2018 Filed Dec 18, 2018 20:20 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | PurchaseCommon Stock | 1,200 | $3.24 | $3,882.00 |
DisclosureSEC source: 0001273636-18-000085 · edgar.xml · nonDerivative · entry 1 Aliski William · CIK 0001598426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,700 F1 · balance_after: Includes 1,500 shares held by the Reporting Person's wife in a self-directed IRA. Read SEC document |
| December 07, 2018 Filed Dec 7, 2018 21:12 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 6,000 | $49.69 | $298,140.00 |
DisclosureSEC source: 0001209191-18-061480 · doc4.xml · nonDerivative · entry 1 Aliski William · CIK 0001598426 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By trust Disclosed balance after: 90,350 F1 · kind: The sale reported on this Form 4 was effected pursuant to a trading plan adopted by the Reporting Person's trust pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's spouse and children. The reporting person's spouse and nephew are trustees of the trust. Read SEC document |
| November 15, 2018 Filed Nov 19, 2018 19:26 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $6.90 | $0.00 |
DisclosureSEC source: 0001273636-18-000065 · edgar.xml · derivative · entry 1 Aliski William · CIK 0001598426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-11-15 F1 · derivative.exercise_date: The option becomes exercisable on November 15, 2019. Read SEC document |
| November 08, 2018 Filed Nov 8, 2018 23:47 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 6,000 | $55.67 | $334,020.00 |
DisclosureSEC source: 0001209191-18-057820 · doc4.xml · nonDerivative · entry 1 Aliski William · CIK 0001598426 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By trust Disclosed balance after: 96,350 F1 · kind: The sale reported on this Form 4 was effected pursuant to a trading plan adopted by the Reporting Person's trust pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's spouse and children. The reporting person's spouse and nephew are trustees of the trust. Read SEC document |
| October 08, 2018 Filed Oct 9, 2018 20:36 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 6,000 | $73.38 | $440,280.00 |
DisclosureSEC source: 0001209191-18-054531 · doc4.xml · nonDerivative · entry 6 Aliski William · CIK 0001598426 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By trust Disclosed balance after: 102,350 F3 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person's trust pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's spouse and children. The reporting person's spouse and nephew are trustees of the trust. Read SEC document |
| September 20, 2018 Filed Sep 24, 2018 21:46 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $4.40 | $0.00 |
DisclosureSEC source: 0001273636-18-000056 · edgar.xml · derivative · entry 1 Aliski William · CIK 0001598426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-09-20 F1 · derivative.exercise_date: The option becomes exercisable in equal yearly installments over three years from the date of grant. Read SEC document |
| August 08, 2018 Filed Aug 8, 2018 21:32 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 3,750 | $76.66 | $287,475.00 |
DisclosureSEC source: 0001209191-18-045878 · doc4.xml · nonDerivative · entry 1 Aliski William · CIK 0001598426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,610 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.6600 to $76.6622 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 19, 2018 Filed Jun 20, 2018 21:50 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $80.69 | $0.00 |
DisclosureSEC source: 0001209191-18-038835 · doc4.xml · derivative · entry 2 Aliski William · CIK 0001598426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2028-06-19 F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 19, 2019. Read SEC document |
| June 19, 2018 Filed Jun 20, 2018 21:50 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-038835 · doc4.xml · nonDerivative · entry 1 Aliski William · CIK 0001598426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,360 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 19, 2019. Read SEC document |
| April 19, 2018 Filed Oct 9, 2018 20:36 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stocki | 650 | $53.97 | $35,080.50 |
DisclosureSEC source: 0001209191-18-054531 · doc4.xml · nonDerivative · entry 5 Aliski William · CIK 0001598426 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By trust Disclosed balance after: 108,350 F2 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's spouse and children. The reporting person's spouse and nephew are trustees of the trust. Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 22:07 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 11,500 | $0.00 Strike: $21.00 | $0.00 |
DisclosureSEC source: 0001209191-18-005421 · doc4.xml · derivative · entry 2 Aliski William · CIK 0001598426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,500 shares Expires 2024-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/3 of the shares initially subject to the option vested one year from January 30, 2014 and then 1/36 of the shares initially subject to the option began vesting monthly thereafter. Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 22:07 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Exercise / conversionCommon Stock | 11,500 | $21.00 | $241,500.00 |
DisclosureSEC source: 0001209191-18-005421 · doc4.xml · nonDerivative · entry 1 Aliski William · CIK 0001598426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,360 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 22, 2017 Filed Jun 22, 2017 23:17 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantEmployee Stock Option (Right to Buy) · Derivative | 3,750 | $0.00 Strike: $65.66 | $0.00 |
DisclosureSEC source: 0001209191-17-041466 · doc4.xml · derivative · entry 2 Aliski William · CIK 0001598426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 3,750 shares Expires 2027-06-22 F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 22, 2018. Read SEC document |
| June 22, 2017 Filed Jun 22, 2017 23:17 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 1,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-041466 · doc4.xml · nonDerivative · entry 1 Aliski William · CIK 0001598426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,860 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 22, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.